NASDAQ$NPCE
Neuropace Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
NeuroPace's Q4 2022 financial results showed revenue growth driven by increased RNS System utilization and initial DIXI Medical product distribution.
NeuroPace reported a 16% increase in total revenue for Q4 2022, reaching $12.8 million. This growth was driven by a 15% increase in initial implant revenue and contributions from the distribution of DIXI Medical products. The company's net loss for the quarter was $11.1 million.
- Total revenue reached $12.8 million, a 16% increase year-over-year.
- Initial implant revenue grew by 15% to $9.8 million compared to the prior year period.
- DIXI Medical product distribution contributed $1.6 million in revenue.
- Gross margin was 69%, down from 73% in the prior year, due to DIXI Medical product sales.
Headline financials
Revenue & EPS history
Neuropace · Revenue · Quarterly
$12.8M
Revenue by segment
Neuropace · $1.6M total across 1 segment · Q4 2022
- DIXI Medical$1.6M—100.0%
Forward guidance
NeuroPace anticipates revenue growth driven by increased RNS System utilization and the full-year impact of DIXI Medical product sales, offset by declining replacement device implant revenue. They expect to substantially complete the transition to the second-generation RNS System by the end of 2023 and do not foresee needing to raise capital in the next 12 months.
Tailwinds
- Total revenue is expected to range between $50.0 million to $52.0 million, growing approximately 10% to 14% over 2022.
- Revenue growth is expected to be primarily driven by increasing utilization of the RNS System.
- Revenue growth is expected to be driven by the full year impact of the sale of DIXI Medical stereo EEG products.
- Gross margin is projected to range between 69% to 71%.
- NeuroPace does not believe that it will have a need to raise capital in the next 12 months.
Headwinds
- Revenue from replacement device implants is expected to decline.
- Replacement implant revenue will generally continue to decrease through the end of 2023.
- Total operating expenses are projected to range between $75.0 million to $77.0 million.
- Ongoing uncertainty of the impact of the COVID-19 pandemic, as well as COVID recovery impact, on NeuroPace’s business.
- Supply chain disruptions.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
-0.7%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-0.0%
Avg return
30 days after
50%
12 / 24 earnings
Positive
+37.4%
Q3 2025
Best reaction
-40.1%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.6% | -1.8% | +0.8% | |
| Q4 2025 | +1.1% | +1.6% | +5.9% | |
| Q3 2025 | +37.4% | +43.1% | +74.5% | |
| Q1 2025 | +21.6% | +31.3% | -14.5% | |
| Q4 2024 | -2.4% | -15.8% | +2.6% | |
| Q3 2024 | +25.7% | +23.4% | +49.9% | |
| Q2 2024 | -1.9% | -0.4% | +4.8% | |
| Q1 2024 | -40.1% | -35.9% | -51.4% | |
| Q4 2023 | +0.8% | +2.5% | -8.4% | |
| Q3 2023 | -1.4% | +9.5% | +14.6% | |
| Q2 2023 | +9.8% | +9.8% | +103.4% | |
| Q1 2023 | +1.9% | -3.5% | -15.4% | |
| Q4 2022 | -13.3% | -7.8% | -1.9% | |
| Q3 2022 | -9.9% | -17.6% | -29.6% | |
| Q2 2022 | -3.5% | -10.2% | -26.6% | |
| Q1 2022 | +1.2% | -3.6% | -3.8% | |
| Q4 2021 | -0.9% | -7.7% | -1.2% | |
| Q3 2020 | -15.2% | -22.2% | -47.7% | |
| Q3 2021 | -15.2% | -22.2% | -47.7% | |
| Q2 2021 | -7.6% | -10.7% | -8.0% | |
| Q2 2020 | -7.6% | -10.7% | -8.0% | |
| Q1 2020 | +0.8% | +8.7% | +2.2% | |
| Q1 2021 | +0.8% | +8.7% | +2.2% | |
| Q4 2020 | +0.8% | +8.7% | +2.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro